17,261 trials
Tumors · Solid Malignant Tumors · Osteosarcoma
Primary: Cohort 1: Recommended Dose (RD) of Lenvatinib — 14 milligram per square meter (mg/m^2)
MItochondrial Myopathies
Primary: Change of Peak Workload (in Watts/kg) During Exercise Testing — 0.0090; 0.020; -0.0300; 0.1050 Watts/kg — p=0.7321
Breast Cancer
Primary: Best Overall Response — 0; 0; 6; 12 participants
Cannabis Abuse · Cannabis Dependence
Primary: Cannabis Use — 55.89; 63.10 Percentage of use days
Dental Plaque
Primary: Change in Whole Mouth Rustogi Modified Navy Plaque Index (RMNPI) Score From Pre-Brushing to Post-Brushing (When Prototype Power Toothbrush [PTB] Was Used in 'Gumline'…
Bronchioloalveolar Carcinoma · Large Cell Lung Carcinoma · Lung Adenocarcinoma
Primary: PFS (Progression Free Survival) — 8; 20 months
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Avoidance of Under-anticoagulation (Peak aFXa <0.2 IU/mL) — 76.6; 79.9 percentage of participants
Breast Cancer · Prostate Cancer · Lung Cancer
Primary: IGF-1 Levels — 73.2; 73.6; 71.2 ng/ml
Epidermolysis Bullosa · Epidermolysis Bullosa Simplex
Primary: Treatment-emergent Adverse Events — 40 Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 5; 7; 6; 8 Participants
Cigarette Smoking
Primary: Number of Participants Smoking-Abstinent for 7 Days, 52 Weeks Post Quit Date — 26; 19 Participants
Parkinson's Disease
Primary: Change From Baseline Moderate-Vigorous Physical Activity Using Actigraph at 4 Months — 2.27; 3.16; 76.96; 75.74 percentage of time
Primary Brain Tumors · Metastatic Malignant Neoplasm to Brain
Primary: Tumor Diameter — 2.7; 4.4 cm
Octreotide · Sputum
Primary: Bronchial Secretion Volume Over Preceding 24 Hour Period — 220; 310; 200; 70 mL/24 hr
Prostate Cancer
Primary: Tumor Growth Rate — 0.031; 0.030 unitless — p=0.74